RCM
DRUG

RA Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

RA Capital Management’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3M Buy
+265,000
New +$21.3M 0.2% 60
2025
Q2 		– Sell
-206,427
Closed -$7.45M – 70
2025
Q1 		$7.45M Sell
206,427
-254,402
-55% -$9.31M 0.12% 70
2024
Q4 		$16.6M Buy
+460,829
New +$16.2M 0.22% 64

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

RA Capital Management's DRUG Position: Q1 2026 in Review

RA Capital Management opened a new position in Bright Minds Biosciences (DRUG) in Q1 2026: 265,000 shares worth $19.3M. The stake represents 0.2% of the portfolio and ranks #60 among its holdings. This is a return to the name: RA Capital Management previously reported a position in DRUG as recently as Q1 2025.

RA Capital Management first reported a position in DRUG in Q4 2024 and has held it in 3 quarters since. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • RA Capital Management held 265,000 shares of Bright Minds Biosciences worth $19.3M as of Q1 2026.
  • Bright Minds Biosciences was a new RA Capital Management position in Q1 2026.
  • Bright Minds Biosciences made up 0.2% of RA Capital Management's portfolio in Q1 2026, its #60 holding.
  • RA Capital Management first reported a position in Bright Minds Biosciences in Q4 2024 and has held it in 3 quarters since.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.